KRAS and cancer: For patients with KRAS WT cancer across all treatment types in the 1L setting, significantly shorter median OS was observed in patients with mSTK11-mKEAP1 vs STK11 WT-KEAP1 WT (5.8 vs 10.1 months; aHR, 1.81; 95% CI, 1.44–2.26; p < 0.001) (Fig. 4A).